ABBV vs. META: AbbVie vs. Meta Platforms Stock Comparison

November 11, 2026

How do AbbVie (ABBV) and Meta Platforms (META) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Meta Platforms (META) belongs to Communication Services (Media & Entertainment) — their GICS classifications point to very different parts of the market.

Company profile comparison for AbbVie (ABBV) and Meta Platforms (META)
Profile Item	ABBV	META
Name	AbbVie Inc.	Meta Platforms Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Communication Services
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Media & Entertainment
GICS Industry	Biotechnology	Interactive Media & Services
GICS Sub-Industry	Biotechnology	Interactive Media & Services
Market Capitalization	514.92 billion USD	1,560.05 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	January 2, 2013	May 18, 2012
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

META

GSPC

AbbVie (ABBV) vs. Meta Platforms (META), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and Meta Platforms (META). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and Meta Platforms (META). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
Total Return (1Y)	37.33%	3.46%
Total Return (3Y, Annualized)	32.74%	26.39%
Total Return (5Y, Annualized)	24.73%	14.05%

Risk Profile

Drawdown History

ABBV

META

GSPC

AbbVie (ABBV) vs. Meta Platforms (META), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and Meta Platforms (META). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
Volatility (1Y, Annualized)	25.65%	41.68%
Beta (5Y)	0.21	1.26
Max Drawdown (5Y)	-21.92%	-74.42%
Avg. Volume (3M)	4.76M	20.91M

Risk-Adjusted Performance

Risk-Return Positioning

ABBV and META are plotted by 1-year volatility (risk) and 1-year return. Each dashed Capital Allocation Line uses that stock's own industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
Sharpe Ratio (1Y)	1.29	-0.02
Sortino Ratio (1Y)	2.02	-0.03

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Meta Platforms (META) earns 32.26% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ABBV: --

Net Margin (TTM)

For every dollar of sales, both AbbVie (ABBV) at 15.67% and Meta Platforms (META) at 31.15% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max: 18.05%
ABBV: 15.67%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Operating Margin (TTM)

Both AbbVie (ABBV) at 39.59% and Meta Platforms (META) at 35.41% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max: 83.12%
ABBV: 39.59%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

META

Media & Entertainment industry group

35.41%

Max: 40.16%
META: 35.41%
Q3: 18.72%
Median: 8.63%
Q1: 1.90%
Min: -22.08%

AbbVie (ABBV) vs. Meta Platforms (META): A comparison of their operating margin against their respective Pharmaceuticals, Biotechnology & Life Sciences and Media & Entertainment industry group benchmarks.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
ROE (TTM)	--	32.26%
ROA (TTM)	10.74%	14.58%
Net Margin (TTM)	15.67%	31.15%
Operating Margin (TTM)	39.59%	35.41%
Gross Margin (TTM)	73.72%	81.03%

Growth

Revenue Growth

Meta Platforms (META) at 22.17% sits in the top revenue growth quartile, while AbbVie (ABBV) at 8.57% is closer to the peer norm — faster top-line expansion for META.

AbbVie (ABBV) vs. Meta Platforms (META): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both AbbVie (ABBV) at -0.84% and Meta Platforms (META) at -1.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

AbbVie (ABBV) vs. Meta Platforms (META): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
Revenue Growth (YoY)	8.57%	22.17%
Revenue Growth (3Y CAGR)	1.75%	19.89%
EPS Growth (YoY)	-0.84%	-1.55%
EPS Growth (3Y CAGR)	-29.03%	39.84%

Financial Strength

Current Ratio (MRQ)

Meta Platforms (META) at 1.90 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ABBV: 0.87
Min: 0.10

META

Media & Entertainment industry group

1.90

Max: 4.69
Q3: 2.53
META: 1.90
Median: 1.52
Q1: 0.95
Min: 0.28

AbbVie (ABBV) vs. Meta Platforms (META): A comparison of their current ratio against their respective Pharmaceuticals, Biotechnology & Life Sciences and Media & Entertainment industry group benchmarks.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Meta Platforms (META) carries debt-to-equity ratio of 0.42 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
Current Ratio (MRQ)	0.87	1.90
Debt / Equity (MRQ)	--	0.42
Net Debt / EBITDA	2.21	0.28

Dividends

Dividend Yield (TTM)

Meta Platforms (META) at 0.35% pays an industry-typical yield; AbbVie (ABBV) at 2.40% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV: 2.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

META

Media & Entertainment industry group

0.35%

Max: 1.33%
Q3: 0.65%
META: 0.35%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Meta Platforms (META): A comparison of their dividend yield against their respective Pharmaceuticals, Biotechnology & Life Sciences and Media & Entertainment industry group benchmarks.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Meta Platforms (META) reports 7.16%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV: 117.35%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
Dividend Yield (TTM)	2.40%	0.35%
Dividend Payout Ratio (TTM)	117.35%	7.16%

Valuation

P/E Ratio (TTM)

Meta Platforms (META) at 20.82 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 50.05 sits in the richer quartile — ABBV needs stronger growth or earnings quality to justify the premium.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max: 85.34
ABBV: 50.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

P/S Ratio (TTM)

AbbVie (ABBV) at 7.80 is priced about in line with its industry on P/S ratio, while Meta Platforms (META) at 6.46 sits in the pricier quartile — META costs more per dollar of sales.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max: 58.18
Q3: 25.77
ABBV: 7.80
Median: 7.30
Q1: 3.01
Min: 0.01

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Meta Platforms (META) reports 5.73, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
ABBV: -112.34

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Meta Platforms (META)
Metric	ABBV	META
P/E Ratio (TTM)	50.05	20.82
P/S Ratio (TTM)	7.80	6.46
P/B Ratio (MRQ)	-112.34	5.73
Free Cash Flow Yield (TTM)	3.44%	1.08%